Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Post-transplant lymphoproliferative disorder (PTLD), drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Rituximab-refractory and EBV-negative PTLD have poor outcomes; EBV-specific T cells, CAR-T and bispecific antibodies are the routes being tested.
US access to tabelecleucel awaits FDA resolution of manufacturing findings; academic virus-specific T-cell banks fill the gap.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Balancing graft rejection against lymphoma control when immunosuppression is reduced; mTOR-inhibitor conversion and tailored regimens are studied.
Preventing PTLD in EBV-seronegative children needing transplants; EBV vaccine candidates are in early trials.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy
First allogeneic T-cell immunotherapy approved; December 2022, for relapsed or refractory EBV-positive PTLD.
Reduce immunosuppression as far as graft safety allows, with close monitoring for rejection; surgery or radiotherapy for localised disease.
Rituximab weekly for four doses; patients in complete remission continue rituximab consolidation alone, others proceed to R-CHOP (PTLD-1 risk-stratified sequential treatment). (NCCN Category 2A)
Overall response 88 percent and complete remission 70 percent with risk-stratified sequential treatment; three-year response duration 82 percent; median overall survival 6.